Catheter Precision Receives Approval for LockeT in the United Kingdom
Catheter Precision (NYSE:VTAK) has received regulatory approval for its LockeT suture retention device in the United Kingdom, following its CE Mark approval in May 2025. The company has partnered with HC21, a major UK-based distributor with 鈧�180 million in annual revenue and 500+ employees across the UK and Ireland.
The LockeT device is designed to enhance patient comfort, enable earlier discharge after cardiac procedures, and support NHS efforts to reduce waiting lists. The company will distribute the product through HC21's established network, leveraging their existing partnership to bring the innovative cardiac device to the UK healthcare market.
Catheter Precision (NYSE:VTAK) ha ottenuto l'autorizzazione normativa per il suo LockeT suture retention device nel Regno Unito, dopo il CE Mark ricevuto nel maggio 2025. L'azienda ha siglato una partnership con HC21, principale distributore con sede nel Regno Unito, che registra ricavi annui di 180 milioni di euro e oltre 500 dipendenti nel Regno Unito e in Irlanda.
Il dispositivo LockeT 猫 progettato per migliorare il comfort del paziente, consentire dimissioni anticipate dopo procedure cardiache e sostenere gli sforzi del NHS per ridurre le liste d'attesa. Il prodotto sar脿 distribuito attraverso la rete consolidata di HC21, sfruttando la loro presenza esistente per introdurre questo dispositivo cardiaco innovativo nel mercato sanitario del Regno Unito.
Catheter Precision (NYSE:VTAK) ha obtenido la aprobaci贸n regulatoria para su LockeT suture retention device en el Reino Unido, tras recibir el marcado CE en mayo de 2025. La compa帽铆a se ha asociado con HC21, un importante distribuidor con sede en el Reino Unido que factura 180 millones de euros anuales y cuenta con m谩s de 500 empleados en Reino Unido e Irlanda.
El dispositivo LockeT est谩 dise帽ado para aumentar la comodidad del paciente, permitir altas m谩s tempranas tras procedimientos card铆acos y apoyar los esfuerzos del NHS para reducir las listas de espera. La empresa distribuir谩 el producto a trav茅s de la red establecida de HC21, aprovechando su colaboraci贸n para introducir este innovador dispositivo cardiaco en el sistema sanitario del Reino Unido.
Catheter Precision (NYSE:VTAK)電� 2025雲� 5鞗� CE 毵堩伂 鞀轨澑鞐� 鞚挫柎 鞓侁淡鞐愳劀 鞛愳偓鞚� LockeT suture retention device鞐� 雽�頃� 攴滌牅 鞀轨澑 鞚� 須嶋摑頄堨姷雼堧嫟. 須岇偓電� 鞐瓣皠 毵れ稖 1鞏� 8觳滊 鞙犽, 鞓侁淡瓿� 鞎勳澕霝滊摐鞐� 500氇� 鞚挫儊鞚� 歆侅洂鞚� 鞛堧姅 鞓侁淡 旮半皹 欤检殧 鞙犿喌靷� HC21鞕� 韺岉姼雱堨嫮鞚� 毵红棃鞀惦媹雼�.
LockeT 鞛レ箻電� 頇橃瀽 韼胳晥頃潉 臧滌劆頃橁碃 鞁灔 鞁滌垹 頉� 臁瓣赴 韲挫洂鞚� 臧�電ロ晿瓴� 頃橂┌, NHS鞚� 雽�旮办瀽 氇呺嫧 臧愳唽 雲鸽牓霃� 歆�鞗愴晿霃勲 靹り硠霅橃棃鞀惦媹雼�. 鞚� 鞝滍拡鞚� HC21鞚� 頇曤霅� 鞙犿喌毵濎潉 韱淀暣 瓿店笁霅橃柎 鞓侁淡 鞚橂 鞁滌灔鞐� 鞚� 順侅嫚鞝侅澑 鞁灔 鞛レ箻毳� 霃勳瀰頃� 鞓堨爼鞛呺媹雼�.
Catheter Precision (NYSE:VTAK) a re莽u l'approbation r茅glementaire pour son LockeT suture retention device au Royaume-Uni, apr猫s l'obtention du marquage CE en mai 2025. La soci茅t茅 s'est associ茅e 脿 HC21, un important distributeur bas茅 au Royaume-Uni r茅alisant 180 millions d'euros de chiffre d'affaires annuel et employant plus de 500 personnes au Royaume-Uni et en Irlande.
Le dispositif LockeT vise 脿 am茅liorer le confort du patient, permettre des sorties plus pr茅coces apr猫s des interventions cardiaques et soutenir les efforts du NHS pour r茅duire les listes d'attente. Le produit sera distribu茅 via le r茅seau 茅tabli de HC21, tirant parti de leur pr茅sence existante pour introduire ce dispositif cardiaque innovant sur le march茅 de la sant茅 britannique.
Catheter Precision (NYSE:VTAK) hat f眉r sein LockeT suture retention device in Gro脽britannien die beh枚rdliche Zulassung erhalten, nach der CE-Kennzeichnung im Mai 2025. Das Unternehmen ist eine Partnerschaft mit HC21 eingegangen, einem gro脽en britischen Vertriebspartner mit einem Jahresumsatz von 180 Mio. 鈧� und 眉ber 500 Mitarbeitern in Gro脽britannien und Irland.
Das LockeT-Ger盲t wurde entwickelt, um den Patientenkomfort zu erh枚hen, fr眉here Entlassungen nach Herzverfahren zu erm枚glichen und die Bem眉hungen des NHS zur Reduzierung von Wartelisten zu unterst眉tzen. Das Produkt wird 眉ber das etablierte Netzwerk von HC21 vertrieben, wodurch deren bestehende Partnerschaft genutzt wird, um dieses innovative Herzger盲t in den britischen Gesundheitsmarkt zu bringen.
- Received UK regulatory approval for LockeT device, expanding market reach
- Partnership with established distributor HC21 (鈧�180M revenue, 500+ employees)
- Product aligns with NHS goals to reduce waiting lists and improve efficiency
- Already secured CE Mark approval in May 2025 for European distribution
- None.
Insights
Catheter Precision expands market reach with UK approval for LockeT device, strengthening European commercial footprint.
Catheter Precision's newly secured UK approval for its LockeT suture retention device represents a significant market expansion following its CE Mark certification in May 2025. The UK registration completes the regulatory requirements needed for commercialization in this key European market.
The distribution partnership with HC21 is particularly strategic given HC21's established presence with 鈧�180 million in annual revenue and over 500 employees across the UK and Ireland. This leverages an existing relationship as Catheter Precision has previously worked with HC21 for other product lines, suggesting operational synergies and established channels.
The LockeT device addresses a specific clinical need in cardiac electrophysiology procedures, with potential to improve patient outcomes while simultaneously offering healthcare system benefits. The company's positioning of the product as supporting NHS efficiency goals by enabling earlier patient discharge aligns with the UK healthcare system's priorities to reduce waiting lists 鈥� a metric where the NHS has recently achieved its first reduction in 17 years.
For Catheter Precision, this approval represents expanded commercial opportunities in the competitive cardiac electrophysiology market. The UK healthcare system, with approximately 100,000 cardiac device procedures annually, represents a substantial market opportunity for specialized devices that can improve procedural efficiency and patient throughput in cardiac care units.
FORT MILLS, S.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced registration and approval in the United Kingdom for its LockeT product, a suture retention device. LockeT received CE Mark for European approval and distribution in May 2025. Obtaining registration was the final approval required to launch sales in the UK.
Catheter Precision has partnered with , a UK-based value-added distributor for several years with a different product line and has entered into an additional agreement to distribute LockeT. With an聽annual revenue of
Fatih Ayoglu, Sales Manager EMEA & APAC, said "We are proud to announce the approval of LockeT for use in the United Kingdom, marking a significant milestone in our mission to support healthcare systems with innovative, patient-centric solutions. LockeT鈥檚 intuitive design and ease of deployment not only enhance patient comfort and recovery but also enable earlier discharge following cardiac procedures. This directly supports NHS efforts to reduce waiting lists by freeing up hospital capacity and accelerating patient throughput. With the NHS recently achieving its first reduction in waiting lists in 17 years, LockeT is poised to contribute meaningfully to this momentum by helping clinicians deliver more treatments, more efficiently. We look forward to working closely with UK healthcare providers to bring LockeT鈥檚 benefits to patients nationwide."
About LockeT
Catheter Precision鈥檚 is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About Catheter Precision
is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as 鈥渂elieve,鈥� 鈥渁nticipate,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥渃an,鈥� 鈥渃ould,鈥� 鈥渃ontinue,鈥� 鈥渄epends,鈥� 鈥渆xpect,鈥� 鈥渆xpand,鈥� 鈥渇orecast,鈥� 鈥渋ntend,鈥� 鈥減redict,鈥� 鈥減lan,鈥� 鈥渞ely,鈥� 鈥渟hould,鈥� 鈥渨ill,鈥� 鈥渕ay,鈥� 鈥渟eek,鈥� or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. 聽These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company鈥檚 expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption 鈥淩isk Factors鈥� in the Company鈥檚 Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
# # #
FAQ
When did Catheter Precision (VTAK) receive UK approval for LockeT?
What is the LockeT device by Catheter Precision (VTAK)?
Who will distribute LockeT in the UK market?
When did Catheter Precision's LockeT receive CE Mark approval?
How will LockeT benefit the UK healthcare system?
